| Harold David Hardman, MD | |
|
N2201 Unc Hospitals, Campus Box 7010, Chapel Hill, NC 27599-0001 | |
| (919) 966-5136 | |
| Not Available |
| Full Name | Harold David Hardman |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 43 Years |
| Location | N2201 Unc Hospitals, Chapel Hill, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558445601 | NPI | - | NPPES |
| 8939414 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 27197 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of North Carolina Hospital | Chapel hill, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unc Physicians And Associates | 0648181156 | 1656 |
News Archive
CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
Shire plc, the global specialty biopharmaceutical company, today announced that the European Medicines Agency has approved the purification of REPLAGAL® (agalsidase alfa) drug substance at its new manufacturing facility in Lexington, MA, US. REPLAGAL, Shire's enzyme replacement therapy for the treatment of Fabry disease is the first product that will be made available to patients from the new facility.
Research about quality of life is improving the treatment of children with velocardiofacial syndrome, a chronic, genetic condition with a wide range of symptoms, including congenital heart disease, palatal abnormalities (e.g. cleft palate), and learning difficulties.
In a published study, a hospital research team from Lawson Health Research Institute has found that expanded dialysis, a new method that removes a broader range of toxins from the body, can improve quality of life in chronic kidney disease patients who struggle with the side effects of traditional dialysis.
Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the Japan Patent Office (JPO) has notified the Max Planck Society of its intent to grant a patent from the Tuschl III patent series (JP Application Number 2003-532675).
› Verified 9 days ago
| Entity Name | University Of North Carolina At Chapel Hill |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780669200 PECOS PAC ID: 0648181156 Enrollment ID: O20031105000359 |
News Archive
CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
Shire plc, the global specialty biopharmaceutical company, today announced that the European Medicines Agency has approved the purification of REPLAGAL® (agalsidase alfa) drug substance at its new manufacturing facility in Lexington, MA, US. REPLAGAL, Shire's enzyme replacement therapy for the treatment of Fabry disease is the first product that will be made available to patients from the new facility.
Research about quality of life is improving the treatment of children with velocardiofacial syndrome, a chronic, genetic condition with a wide range of symptoms, including congenital heart disease, palatal abnormalities (e.g. cleft palate), and learning difficulties.
In a published study, a hospital research team from Lawson Health Research Institute has found that expanded dialysis, a new method that removes a broader range of toxins from the body, can improve quality of life in chronic kidney disease patients who struggle with the side effects of traditional dialysis.
Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the Japan Patent Office (JPO) has notified the Max Planck Society of its intent to grant a patent from the Tuschl III patent series (JP Application Number 2003-532675).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Harold David Hardman, MD N2201 Unc Hospitals, Campus Box 7010, Chapel Hill, NC 27599-0001 Ph: (919) 966-5136 | Harold David Hardman, MD N2201 Unc Hospitals, Campus Box 7010, Chapel Hill, NC 27599-0001 Ph: (919) 966-5136 |
News Archive
CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
Shire plc, the global specialty biopharmaceutical company, today announced that the European Medicines Agency has approved the purification of REPLAGAL® (agalsidase alfa) drug substance at its new manufacturing facility in Lexington, MA, US. REPLAGAL, Shire's enzyme replacement therapy for the treatment of Fabry disease is the first product that will be made available to patients from the new facility.
Research about quality of life is improving the treatment of children with velocardiofacial syndrome, a chronic, genetic condition with a wide range of symptoms, including congenital heart disease, palatal abnormalities (e.g. cleft palate), and learning difficulties.
In a published study, a hospital research team from Lawson Health Research Institute has found that expanded dialysis, a new method that removes a broader range of toxins from the body, can improve quality of life in chronic kidney disease patients who struggle with the side effects of traditional dialysis.
Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the Japan Patent Office (JPO) has notified the Max Planck Society of its intent to grant a patent from the Tuschl III patent series (JP Application Number 2003-532675).
› Verified 9 days ago
Dr. Brian P Barrick, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: N2198 Unc Hospitals Clb # 7010, Department Of Anesthesiology, Chapel Hill, NC 27599 Phone: 919-966-5136 Fax: 984-971-4873 | |
Priya Kumar, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: N2198 Unc Hospitals Cb 7010, Department Of Anesthesiology, Chapel Hill, NC 27599 Phone: 919-966-5136 Fax: 984-974-4873 | |
Dr. David C Mayer, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27599 Phone: 919-966-8596 Fax: 919-843-5515 | |
Kathryn Watson Cobb, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Room 1107g West Wing, Chapel Hill, NC 27514 Phone: 919-966-1072 Fax: 919-966-0290 | |
Dr. Jeremy D Deer, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 984-974-1000 | |
Jeremy Armbruster, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 984-974-1000 | |
Dr. Paul M Collins Jr., D.O. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 101 Manning Dr, Cb#7010, N2201 Unc Hospitals, Chapel Hill, NC 27599 Phone: 919-966-8596 Fax: 919-843-5515 |